DENTSPLY SIRONA Inc.
XRAY Healthcare Medical Instruments & Supplies
DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024.
- Revenue
- −7.52%
- EPS
- +99.5%
- Free cash flow
- −18.0%
- Total debt
- −1.59%
Quarter to September 2026, against a year earlier
Follow XRAY
Alert me
DENTSPLY SIRONA Inc. (XRAY) P/S ratio
As of 5 November 2026, DENTSPLY SIRONA Inc. (XRAY) trades at a P/S ratio of 0.6×. Over the past ten years it has ranged from 0.5× (October 2026) to 4.9× (August 2016); the current reading is higher than 2% of that period. That is below the Medical Instruments & Supplies industry median of 2.5× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 0.6× | (39.09%) |
| FY2024 | 1.0× | (46.63%) |
| FY2023 | 1.9× | 6.06% |
| FY2022 | 1.8× | (37.63%) |
| FY2021 | 2.9× | (16.22%) |
| FY2020 | 3.4× | 9.51% |
| FY2019 | 3.1× | 49.91% |
| FY2018 | 2.1× | (45.71%) |
| FY2017 | 3.9× | 13.03% |
| FY2016 | 3.4× | 7.11% |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 0.5× | (15.11%) |
| Jun 2026 | 0.6× | (7.67%) |
| Mar 2026 | 0.6× | 1.71% |
| Dec 2025 | 0.6× | (11.35%) |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| XRAY DENTSPLY SIRONA Inc. | 0.6× |
| STVN Stevanato Group S.p.A. compare | 2.5× |
| AZTA Azenta, Inc. compare | 2.8× |
| WRBY Warby Parker Inc. compare | 3.5× |
| STAA STAAR Surgical Company compare | 4.1× |
| ATRC AtriCure, Inc. compare | 5.0× |
| LMAT LeMaitre Vascular, Inc. compare | 7.0× |
| KMTS Kestra Medical Technologies, Ltd. compare | 15.3× |
| PLSE Pulse Biosciences, Inc compare | 2,559× |
| Medical Instruments & Supplies industry median | 2.5× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on XRAY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement